TBLI and HIV.  30% of People infected with HIV/AIDS and have latent TB will eventually get active TB (5 -10% /year).In HIV negative 5-10 % during their.

Slides:



Advertisements
Similar presentations
Contact Evaluation Your name Institution/organization Meeting Date International Standards 18, 19.
Advertisements

Discussion group 1 TB preventive therapy for PLWHA Alasdair Reid for Fabio Scano THD unit Stop TB department WHO.
TB/HIV Research Priorities: TB Preventive Therapy.
A typical day in the TB clinic You see the following patients in the TB clinic. All have normal CXRs: 1. A 35 year old man from Hartford with a 16 mm positive.
CHER Trial: Early Antiretroviral Therapy and Mortality Among HIV- Infected Infants New England J Med 2008;359 (21):
Tuberculosis in Children: Prevention Module 10C - March 2010.
Continuity Clinic Tuberculosis. Continuity Clinic Objectives Know current epidemiologic trends in TB Know indications for testing for TB exposure and.
TB Contact Investigation
Case Discussion: TB in Pregnancy December 15, 2010 E. Jane Carter, M.D.
Wyoming Department of Health Communicable Diseases
Screening of Latent Tuberculosis before treatment with TNF  blockers Ori Elkayam M.D Tel Aviv Medical Center.
HIV Care Continuum for the United States and Puerto Rico National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention Division of HIV/AIDS Prevention.
Unit 5: IPT Isoniazid TB Preventive Therapy
Current international guidelines recommend 6–9 months of isoniazid (INH) preventive chemotherapy to prevent the development of active tuberculosis in.
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
Paediatric Tuberculosis in HIV Era
TUBERCULOSIS * Prevention * Treatment, and * Challenges.
Module 14: Isoniazid Preventive Therapy Programme.
IMPLEMENTATION PLAN TO SCALE UP HIV/AIDS PREVENTION AND TREATMENT 1.
Tuberculosis in Pregnancy Max Brinsmead MB BS PhD May 2015.
Unit 7 Treatment of TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Johns Hopkins Center for Tuberculosis Research
Use of 12 weekly doses of isoniazid and rifapentine for the treatment of latent tuberculosis − Connecticut , Kelley Bemis, MPH CDC/CSTE Applied.
Determination of HIV Infection Among TB Patients in California, 2008 Darryl Kong 1, Jennifer Flood 1, Suzanne Marks 2, James Watt 1 1 California Department.
Extrapulmonary Site 2 :_____________________ Name (surname, first name) Age (in years) Sex F Alternative address Physical Address (in full) M INTERIM TUBERCULOSIS.
Welcome to I-TECH Nurse Clinical Seminar Series 19 August WHO Recommendations for TB Screening and IPT among People Living with HIV Stacie C.
Progress toward COP 12 targets Mozambique-ICB October
Outcomes among patients with HIV- associated Tuberculosis in Guangxi, People’s Republic of China Zhang Yao, Yu Lan, Ma Ye, Zhao Yan, Sun Kai and Zhang.
Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.
Progress of the Singapore TB Elimination Programme (STEP)
Tuberculosis in Virginia? Wendy Heirendt, MPA Public Health Advisor Division of TB Control Virginia Department of Health September 12, 2005.
Coordinator: Kézdi- Zaharia E. Iringó First author: Magyar Júlia Coauthor: Gyerő Réka.
Tuberculosis in the United States National Tuberculosis Surveillance System Highlights from 2011 National Center for HIV/AIDS, Viral Hepatitis, STD, and.
PREVALENCE OF MDR-TB AMONGST PATIENTS WITH HIV AND TB CO- INFECTION SEEN AT THE DOTS CLINIC OF N.I.M.R., LAGOS, NIGERIA. Enya V.N.V, Onubogu C.C., Wahab.
TB-HIV INTEGRATION IN THE WORKPLACE 2 nd Private Sector Conference on HIV and AIDS Presenter: Dr S Charalambous.
HIV/TB – Case Studies David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Health.
HIV/TB Integration in a Network of Voluntary Counseling/Testing Centers in HAITI Reynold Grand’Pierre MD, Marie Suze Jacquet MD, Jean W. Pape MD PEPFAR.
Haileyesus Getahun Stop TB Department WHO Re-conceptualizing ICF and IPT: global progress to date 14 th Core Group Meeting of the TB/HIV Working Group,
Extrapulmonary Site 2 :_____________________ TUBERCULOSIS TREATMENT CARD BOTSWANA NATIONAL TUBERCULOSIS PROGRAMME Date RegisteredIN ToOUT RegisteredIN.
Colleen Daniels Stop TB Department World Health Organisation TB, HIV and Drug Use The overview.
Tuberculosis August 17, 2010 Tuberculosis Mycobacterium tuberculosis – Fastidious, aerobic, acid-fast bacillus Tremendous increase in incidence over.
Prophylaxis of Opportunistic Infections
Collaborative TB/HIV Activities. Collaborative TB/HIV activities A.To establish the mechanisms for collaboration B.To decrease the burden of TB in PLWHA.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
Diagnostics - More than 100 years old Drugs – Last drug 40 years old Vaccine – Nearly 90 years old Lucica Ditiu Executive Secretary, Stop TB Partnership.
TB Prevention and Control in Correctional and Detention Facilities Mark Lobato, MD Division of TB Elimination Centers for Disease Control and Prevention.
Progress toward COP 12 targets DRC October
LEARNING MODULE TITLE SUBTITLE. HISTORY OF PRESENT ILLNESS An 18 year-old woman with no past medical history and no known risks for TB presents with several.
The Epidemiology of Tuberculosis Lex Gibson, Director Virginia TB Program.
T T H H I I Tennessee Health Indicators PROGRAM DIRECTOR: DR. JON WARKENTIN DATA DIRECTOR/EPIDEMIOLOGIST: JASON CUMMINS, MPH Tuberculosis Elimination Program.
TB-H V Co-infection by Dr. Ker Hong Bee 11. LEARNING OBJECTIVES To know & understand about TB-HIV co- infection in relation to:- – interaction & prevalence.
MYCOBACTERIA Dr.Qurat-Ul-Ain Senior Demonstrator Microbiology, KEMU, Lahore.
Case Discussion 2 - TB IN CHILDREN by Dr. Jeyaseelan P. Nachiappan & Dr. Suryati Adnan 1 Picture of CPG Cover.
Subcutaneous abatacept compassionate use program: South African real-world data provides further insight into the safety of subcutaneous abatacept in a.
Guidance on completion of Isoniazid Preventive Therapy register
TUBERCULOSIS IN JAPAN ANNUAL REPORT – 2016.
Copyright © 2006 American Medical Association. All rights reserved.
Tolerability of Isoniazid Preventive Therapy (IPT) in an HIV infected cohort
Treatment of Latent TB Infection (LTBI)
Figure 1. Paradigm for evaluation of those with latent tuberculosis infection (LTBI) based on risk of infection, risk of progression to tuberculosis, and.
TUBERCULOSIS IN VIRGINIA
World Health Organization
Advanced HIV: a WHO perspective
Tolerability of Isoniazid Preventive therapy Among HIV infected Cohort in Nigeria Folajinmi Oluwasina Strategic Information Unit AIDS Healthcare Foundation,
Tuberculosis Global Epidemiology
Anthony D Harries Ministry of Health, Malawi
Surveillance for TB in HIV Care and Treatment Settings (CTS)
Geneva, Switzerland June 2002
Collaborative TB/HIV activities 2011 Tables, Graphs & Maps
5th edition NTP MANUAL OF PROCEDURES Case Finding
Presentation transcript:

TBLI and HIV

 30% of People infected with HIV/AIDS and have latent TB will eventually get active TB (5 -10% /year).In HIV negative 5-10 % during their life.

It is known that treatment of latent TB infection(LTBI) or TB preventive therapy, helps to prevent progression to active disease

 Isoniazid prevention therapy (IPT ) 6-12 months

PREVALENCE OF ACTIVE TB IN PEOPLE WITH HIV WHO HAVE LATENT TB AND TREATED WITH INH FOR 6 MONTHS FROM S.mansuri M.HajiabdolbaghiM.Hasibi

Inclusion criteria HIV positive who have been treated with INH for 6 months and fallowed up for 1 year after Exclusion criteria Sputum AFB positive during INH prophylaxis CxR or CT compatible with TB Pathology compatible with TB LTBI prophylaxis with other drug except INH

Results

Table - 1 TST result NumbersPercentTST Positive Negative TST was done TST was not done Sum

In this study TST was done in67.2% of all HIV patients in our center. This rate in other studies was between 50 %- 79%

TST number Positive number Percent 1128 (M.haji) NA (mohraz) NA25% NA(alavi)NA54.5 NA (Alaee) NA88% NA(Shokoohi)NA39.4

In other studies prevalence of TBLI in HIV positive from 25% to 46% is reported.

TST Prophylaxis numberpercent INH prophylaxis No INH prophylaxis 6.93 PZA,RIF prophylaxis Sum Sum

 In other studies( WHO.USA. Brasilia) 25%,46% 59.8% HIV positive patient with LTB have received IPT

Mean follow up period was 3.5 ( 1.5± 3.5 )

PPD+ PPD- INH≥6m INH-INH<6m Cases Number TB cases TB% /49 TB cases in PPD+ and PPD -

Variable Age 57/ 8± 39.75) Sex M 264 (85%) F46 (15%) CD ART yes 218(70/3%) yes 218(70/3%) No 92 (29/7%)

76% of our cases had compliance to prophylaxis 76% of our cases had compliance to prophylaxis

Mean period of time between IPT to treatment of TB in 6 TB cases was 24.7 months

 1672 PPD - No PPD PPD INH+397INH Z+R6

134 TB cases PPD No PPD No IPT PPD+ INH <6 mo Complete IPT 62.6

TB before HIV diagnosis TB after HIV diagnosis TB,HIV same time 3828,35 ART before TB diagnosis ART after TB diagnosis TB cases

TB after ARV